Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Journal of Electrocardiology|January 13, 2004
Identification of sotalol-induced changes in repolarization with T wave area-based repolarization duration parametersJean-Philippe Couderc, Wojciech Zareba, Arthur J Moss, et al.
The American Journal of Gastroenterology|October 3, 2002
Tegaserod, a 5-hydroxytryptamine type 4 receptor partial agonist, is devoid of electrocardiographic effectsJoel Morganroth, Peter C Rüegg, Cornelia Dunger-Baldauf, et al.
British Journal of Clinical Pharmacology|May 27, 2015
Moxifloxacin-induced QTc interval prolongations in healthy male Japanese and Caucasian volunteers: a direct comparison in a thorough QT studyJoel Morganroth, Yaning Wang, Michael Thorn, et al.
Clinical Pharmacology in Drug Development|May 23, 2018
A Thorough QT/QTc Study With Laquinimod, a Novel Immunomodulator in Development for Multiple Sclerosis and Huntington DiseaseOfer Spiegelstein, Dorit Mimrod, Laura Rabinovich, et al.
Cancer Chemotherapy and Pharmacology|February 2, 2012
Midostaurin does not prolong cardiac repolarization defined in a thorough electrocardiogram trial in healthy volunteersAdam del Corral, Catherine Dutreix, Alice Huntsman-Labed, et al.
Medicine|November 18, 2008
Arrhythmias in patients with chronic obstructive pulmonary disease (COPD): occurrence frequency and the effect of treatment with the inhaled long-acting beta2-agonists arformoterol and salmeterolJohn P Hanrahan, Donna R Grogan, Rudolf A Baumgartner, et al.
British Journal of Clinical Pharmacology|April 22, 2010
No cardiac effects of therapeutic and supratherapeutic doses of rupatadine: results from a 'thorough QT/QTc study' performed according to ICH guidelinesEster Donado, Iñaki Izquierdo, Iñaki Pérez, et al.
The American Journal of Cardiology|May 29, 2004
Evaluation of vardenafil and sildenafil on cardiac repolarizationJoel Morganroth, Bernard E Ilson, Bonnie C Shaddinger, et al.
Cancer Chemotherapy and Pharmacology|May 27, 2015
Effect of bendamustine in combination with rituximab on QT interval duration in patients with advanced de novo indolent non-Hodgkin or mantle cell lymphomaJohn M Burke, Richard H C van der Jagt, Ian W Flinn, et al.
The Annals of Pharmacotherapy|March 18, 2004
Clinical experience with moxifloxacin in patients with respiratory tract infectionsGerald A Faich, Joel Morganroth, Alan B Whitehouse, et al.
Pageof 4